Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.

Enochian Biosciences, Inc.

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.

Eterna Therapeutics Inc.

GC Therapeutics harnesses an induced pluripotent stem cell (iPSC) cellular programming platform to improve patient access across various therapeutic areas, focusing on gastrointestinal, neurological, and immunological diseases.

GC Therapeutics

Renovaro Biosciences develops advanced cell, gene, and immunotherapy platforms for oncology. It focuses on diagnostics and therapies for cancer treatment, utilizing AI and liquid biopsies.

Metric
Company Name	Enochian Biosciences, Inc.	Eterna Therapeutics Inc.	GC Therapeutics
Symbol	ENOB	ERNA
MSH ID	COM:ENOCHIANBIO	COM:ETERNATX	COM:GC-TX
Market	STOCKS	STOCKS	PRIVATE
Sector	Healthcare	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Biotechnology
Country	US	US	US
Stage			Series A
Employee Count	22	8
Website	enochianbio.com	brooklynitx.com	gc-tx.com
LinkedIn
Founders

Metric
Market Cap	45.38M	9.90M
Enterprise Value
Monthly Web Traffic	80	270.57K	1.68K
Web Traffic Growth	-0.89	0.55	-0.43
Valuation
Raised Capital			65M

Metric
Revenue		68K
Revenue (LTM)
Revenue (NTM)
Gross Profit		-1.29M
EBITDA		-19.55M
Operating Income		-20.67M
Net Income		-21.67M
EPS		-4.08
Diluted EPS		-4.08
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		-5.88
Operating Profit Margin		-135.73
EBITDA Margin		-287.51
Net Profit Margin		-147.65
Return on Equity		15.58
Return on Assets		-0.44
Return on Capital Employed		-0.50

COM:ENOCHIANBIO

Renovaro Biosciences

Last Close

0.70

04/08 19:58

Market Cap

45.38M

Beta: -

Volume Today

87.29K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-0.42
P/B Ratio		2.34
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		192.73
EV Multiple		2.09

Metric
Days Sales Outstanding		12.71K
Days Payables Outstanding		4.45K
Days Inventory Outstanding
Operating Cycle		2.28K
Cash Conversion Cycle		1.79K
Asset Turnover		0.00

Metric
Operating Cash Flow		-20.41M
Free Cash Flow		-20.43M
Cash Flow to Debt		-0.38
Operating Cash Flow/Sales		-101.81
Free Cash Flow Yield		-2.54

Metric
Cash & Equivalents		7.58M
Accounts Receivable		527K
Inventory
Goodwill		2.04M
Debt to Capitalization		2.84
Debt to Assets		0.79
Current Ratio		0.73
Quick Ratio		1.22

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		28.90
R&D to Revenue		130.82
SG&A to Revenue		252.08